Repurposing Simvastatin as a Therapeutic Strategy to Treat p53 Mutant Solid Tumors
M Pereira - 2022 - atrium.lib.uoguelph.ca
For the past 30 years, the standard of care for epithelial ovarian cancer has essentially
remained unchanged with little progress in the development of novel innovative treatments …
remained unchanged with little progress in the development of novel innovative treatments …
[PDF][PDF] Repurposing Simvastatin as a Therapeutic Strategy to Treat p53 Mutant Solid Tumors
M Pereira - 2023 - atrium.lib.uoguelph.ca
High-grade serous carcinoma (HGSC) is the most common and aggressive subtype of
epithelial ovarian cancer and is characterized by gain-of-function TP53 mutations originating …
epithelial ovarian cancer and is characterized by gain-of-function TP53 mutations originating …